Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.74 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.56 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TCF4 | P15884 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18257903 | 0.87 | CTNNB1 (1.00) | CTNNB1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL20147884 | 0.85 | CTNNB1 (0.79) | CTNNB1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL18249656 | 0.84 | CTNNB1 (1.00) | CTNNB1KDM4ETCF4 | |
| SCHEMBL4376300 | 0.82 | ALDH1A1 (0.84) | CTNNB1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL20147874 | 0.81 | CTNNB1 (0.67) | CTNNB1ALDH1A1HSD17B10KDM4ETSHR | |
| SCHEMBL18257906 | 0.81 | CTNNB1 (1.00) | CTNNB1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL20149720 | 0.80 | CTNNB1 (0.85) | CTNNB1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL20147882 | 0.79 | CTNNB1 (0.78) | CTNNB1ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL20147881 | 0.79 | CTNNB1 (0.70) | CTNNB1ALDH1A1HSD17B10KDM4ETSHR | |
| SCHEMBL20147875 | 0.79 | CTNNB1 (0.80) | CTNNB1ALDH1A1HSD17B10KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299123-A1 | SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-30 | — | — | US | disclosed |
| US-10273246-B2 | Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273246-B2 | Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH | 2018-05-17 | — | — | US | disclosed |
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH | 2018-05-17 | — | — | US | disclosed |
| WO-2016187050-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5]OXADIAZOLO[3',4':5,6] PYRAZIONO[2,3-B]INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134729-A1 | METHODS AND COMPOSITIONS OF SUBSTITUTED 5H-[1,2,5] OXADIAZOLO [3',4':5,6] PYRAZINO[2,3-B] INDOLE ANALOGS AS INHIBITORS OF BETA-CATENIN/T-CELL FACTOR PROTEIN-PROTEIN INTERACTIONS | CTNNB1, CTNNBL1, WNT3A | CTNNB1 1/4885ALDH1A1 4213/4885HSD17B10 3431/4885 |
| US-20210299123-A1 | SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF | XIAP, BIRC5, TP53 | CTNNB1 1509/4885ALDH1A1 2712/4885HSD17B10 4203/4885 |
| US-10273246-B2 | Methods and compositions of substituted 5H-[1,2,5] oxadiazolo [3′,4′:5,6] pyrazino[2,3-B] indole analogs as inhibitors of β-catenin/T-cell factor protein-protein interactions | CTNNB1, CTNNBL1, WNT3A | CTNNB1 1/4885ALDH1A1 4237/4885HSD17B10 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.